TITLE

Fabry disease — A challenge for diagnosis and treatment

AUTHOR(S)
VINTILA, Vlad; ENESCU, Oana
PUB. DATE
December 2008
SOURCE
Maedica - a Journal of Clinical Medicine;2008, Vol. 3 Issue 4, p270
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents information on Fabry disease, a genetically inherited lysosomal storage disease which is characterized by intracellular and plasmatic accumulation of glycosphingolipids. The gene responsible for the disease is located on the X chromosome, due to which it has an X-linked recessive transmission. In Fabry disease, pain may occur daily in the hands and feet. It is stated that Fabry-related cardiovascular disease is the main cause of premature death. Gastrointestinal symptoms of Fabry disease include abdominal cramping and pain, diarrhea, constipation, nausea, and vomiting.
ACCESSION #
36124663

 

Related Articles

  • The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Gal, Andreas; Ries, Markus; Beck, Michael; Whybra, Catharina; Ramaswami, Uma; Parini, Rossella; Lind blad, Bengt; Willers, Ingrid // European Journal of Pediatrics;2003, Vol. 162 Issue 11, p767 

    Fabry disease (FD) is a debilitating progressive multisystem X-linked lysosomal storage disorder. It was generally believed that the disease affects only adult males. Through systematic pedigree analysis, we identified 35 paediatric FD patients (age 1 to 21 years, mean 12.6 years) in 25...

  • Agents for the Treatment of Glycosphingolipid Storage Disorders. Abe, A.; Wild, S.R.; Lee, L.; Shayman, J.A. // Current Drug Metabolism;Sep2001, Vol. 2 Issue 3, p331 

    We have developed a series of inhibitors of glucosylceramide synthase that are Structurally based on the parent compound D-threo-1-phenyl-2-decanoylamino-3- morpholino-1-propanol (PDMP). These inhibitors provide useful tools for manipulating glycosphingolipid levels in cells and for elucidating...

  • Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy. Desnick, Robert J.; Brady, Roscoe; Barranger, John; Collins, Allan J.; Germain, Dominique P.; Goldman, Martin; Grabowski, Gregory; Packman, Seymour; Wilcox, William R. // Annals of Internal Medicine;2/18/2003, Vol. 138 Issue 4, p338 

    Provides clinical guidelines on the diagnosis and treatment of Fabry disease, an X-linked recessive lysosomal storage disorder. Disease pathophysiology; Clinical manifestations; Clinical trials of enzyme replacement therapy in patients with Fabry disease; Recommendations for diagnosis and...

  • EDITOR'S QUIZ: GI SNAPSHOT: A male with pelvic mass. Kjossov, K. T.; Vladov, N. N.; Losanoff, J. E. // Gut;Aug2004, Vol. 53 Issue 8, p1122 

    This article presents a quiz related to a clinical case study of a male with a pelvic mass. In the present case, 40 year old man presented to the emergency department with a six day history of intermittent abdominal left lower quadrant pain, nausea, vomiting, and constipation. On Physical...

  • X chromosome:. Schlegel, Rolf H. J. // Encyclopedic Dictionary of Plant Breeding & Related Subjects;2003, p435 

    An encyclopedia entry for "X chromosome," which refers to the sex chromosome found in the homogametic and heterogametic sex.

  • Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections. Valbuena, Carmen; Leitão, Dina; Carneiro, Fátima; Oliveira, João // Virchows Archiv;Feb2012, Vol. 460 Issue 2, p211 

    Fabry disease (FD) is a rare X-linked lysosomal storage disorder of glycosphingolipids, mostly globotriaosylceramide (Gb3). Proteinuric chronic kidney disease develops frequently, and recognition of Fabry nephropathy on a kidney biopsy may be the first clue to the underlying diagnosis. Since the...

  • Increased globotriaosylceramide levels in a transgenic mouse expressing human α1,4-galactosyltransferase and a mouse model for treating Fabry disease. Shiozuka, Chikara; Taguchi, Atsumi; Matsuda, Junichiro; Noguchi, Yoko; Kunieda, Takanori; Uchio-Yamada, Kozue; Yoshioka, Hidekatsu; Hamanaka, Ryoji; Yano, Shinji; Yokoyama, Shigeo; Mannen, Kazuaki; Kulkarni, Ashok B.; Furukawa, Koichi; Ishii, Satoshi // Journal of Biochemistry;Feb2011, Vol. 149 Issue 2, p161 

    Fabry disease is a lysosomal storage disorder caused by an α-galactosidase A (α-Gal A) deficiency and resulting in the accumulation of glycosphingolipids, predominantly globotriaosylceramide (Gb3). A transgenic mouse expressing the human α-Gal A R301Q mutant in an α-Gal A-knockout...

  • Fabry's disease: An ultrastructural study of nerve biopsy. Gayathri, N.; Yasha, T. C.; Kanjalkar, Makarand; Agarwal, Santosh; Sagar, B. K. Chandrashekar; Santosh, Vani; Shankar, S. K. // Annals of Indian Academy of Neurology;Jul2008, Vol. 11 Issue 3, p182 

    Fabry's disease, an X linked recessive disorder caused by the deficiency of α-galactosidase A (α-gal A), leads to progressive accumulation of glycosphingolipids. We report this rare disease in a 19-year-old boy who presented with angiokeratomas, paresthesia and corneal opacities, and nerve...

  • Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. Germain, Dominique P.; Avan, Paul; Chassaing, Augustin; Bonfils, Pierre // BMC Medical Genetics;2002, Vol. 3, p10 

    Background: Fabry disease (FD, OMIM 301500) is an X-linked inborn error of glycosphingolipid metabolism due to the deficient activity of alpha-galactosidase A, a lysosomal enzyme. While the progressive systemic deposition of uncleaved glycosphingolipids throughout the body is known to have...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics